Mallinckrodt/NeoRx agreement
Executive Summary
International Minerals & Chemical subsidiary Mallinckrodt acquires minority equity position in Seattle-based monoclonal antibody research firm NeoRx. Mallinckrodt will recieve "certain exclusive technology, product development and marketing rights in the field of radioisotopic imaging agents utilizing monoclonal antibodies," a March 18 release notes. Under the agreement, Mallinckrodt will get access to diagnostic products stemming from NeoRx research in the monoclonal antibody area.
You may also be interested in...
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.
Lilly Can Rest Easy As Tirzepatide Scores Phase III Sleep Apnea Win
Topline results from two studies in obstructive sleep apnea among obese adults showed efficacy crossing the 50% threshold that physicians have called clinically meaningful.